Focusing prostate cancer testing on men at highest risk of developing the disease is likely to improve the ratio between benefits and the harms of screening, suggests a paper published today in BMJ.

For decades, men with prostate cancer were routinely advised against testosterone replacement therapy (TRT), even if they had ...

An updated Cochrane review has found that prostate-specific antigen (PSA) screening probably reduces deaths from prostate cancer — a notable shift from the influential group’s 2013 conclusion that ...

Prostate cancer is the second most common cancer in men globally. Early detection through screening has long been debated, as experts are divided on whether the benefits outweigh the risks of ...

Investigators sought to model the effects of relabeling GG1 prostate cancer as precancerous on prostate cancer mortality in the US.

May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...

Experts say prostate cancer remains a leading cause of cancer deaths in men. But new research at Yale shows that is likely to change. Dr. Nicholas Brutus, urology resident and lead author at the Yale ...

Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from the previous version of the review ...

Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', ...

Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated review finds. This is a shift from the previous version of the review, which ...